18F-Fluoroestradiol

Seminars in Nuclear Medicine

Volumn 37, Issue 6, 2007, Pages 470-476

  Sundararajan, Lavanya ^a   Linden, Hannah M ^a   Link, Jeanne M ^b   Krohn, Kenneth A ^b   Mankoff, David A ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; FLUORINE 18; FLUOROESTRADIOL F 18; MOXESTROL F 18; TAMOXIFEN; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

BREAST CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOSIMETRY; DRUG CLEARANCE; DRUG EXCRETION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; BREAST TUMOR; FEMALE; METABOLISM; NEOPLASM; SCINTISCANNING;

BREAST NEOPLASMS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, ESTROGEN;

EID: 34848825649     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2007.08.003     Document Type: Review

References (46)

1. Pujol P., Hilsenbeck S.G., Chamness G.C., et al. Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer 74 (1994) 1601-1606
2. Osborne C.K., Yochmowitz M.G., Knight III W.A., et al. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46 suppl 12 (1980) 2884-2888
3. Bloom N.D., Tobin E.H., Schreibman B., et al. The role of progesterone receptors in the management of advanced breast cancer. Cancer 45 (1980) 2992-2997
4. Briasoulis E., Karavasilis V., Kostadima L., et al. Metastatic breast carcinoma confined to bone: Portrait of a clinical entity. Cancer 101 (2004) 1524-1528
5. Buzdar A., Douma J., Davidson N., et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19 (2001) 3357-3366
6. Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19 (2001) 2596-2606
7. Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial Arimidex Study Group. J Clin Oncol 18 (2000) 3758-3767
8. Kuukasjarvi T., Kononen J., Helin H., et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14 (1996) 2584-2589
9. Spataro V., Price K., Goldhirsch A., et al. Sequential estrogen receptor determinations from primary breast cancer and at relapse: Prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol 3 (1992) 733-740
10. Hull D., Clark G., Osborne C., et al. Multiple estrogen receptor assays in human breast cancer. Cancer Res 43 (1983) 413-416
11. Mankoff D.A., Deshdashti F., and Shields A.F. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia 2 (2000) 71-88
12. Katzenellenbogen J.A., Welch M.J., and Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res 17 (1997) 1573-1576
13. Kiesewetter D.O., Kilbourn M.R., Landvatter S.W., et al. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med 25 (1984) 1212-1221
14. 18F]fluoroestradiols: Selective receptor-based PET imaging agents. Int J Rad Appl Instrum B 19 (1992) 363-374
15. 18F]fluoronor-hexestrol), a positron-emitting estrogen that shows highly-selective, receptor-mediated uptake by target tissues in vivo. Life Sci 33 (1983) 1933-1938
16. 18F]fluorine substitution at the 16alpha-position of fulvestrant (faslodex; ICI 182,780). Nucl Med Biol 31 (2004) 691-698
17. 18F-labeled difluoroestradiols: Preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids 67 (2002) 765-775
18. Cummins C.H. Radiolabeled steroidal estrogens in cancer research. Steroids 58 (1993) 245-259
19. Jonson S.D., and Welch M.J. PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Q J Nucl Med 42 (1998) 8-17
20. 18F]fluoromoxestrol in isolated hepatocytes. Nucl Med Biol 26 (1999) 123-130
21. Petra P.H. The plasma sex steroid binding protein (SBP or SHBG). A critical review of recent developments on the structure, molecular biology and function. J Steroid Biochem Mol Biol 40 (1991) 735-753
22. Aliaga A., Rousseau J.A., Cadorette J., et al. A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18]fluoro-D-glucose in murine models of breast cancer. Mol Imaging Biol 9 (2007) 144-150
23. Aliaga A., Rousseau J.A., Ouellette R., et al. Breast cancer models to study the expression of estrogen receptors with small animal PET imaging. Nucl Med Biol 31 (2004) 761-770
24. Seo J.W., Comninos J.S., Chi D.Y., et al. Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: Synthesis and structure-affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer. J Med Chem 49 (2006) 2496-2511
25. Brodack J.W., Kilbourn M.R., Welch M.J., et al. Application of robotics to radiopharmaceutical preparation: controlled synthesis of fluorine-18 16 alpha-fluoroestradiol-17 beta. J Nucl Med 27 (1986) 714-721
26. Lim J.L., Zheng L., Berridge M.S., et al. The use of 3-methoxymethyl-16 beta, 17 beta-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-18 16alpha-fluoroestradiol. Nucl Med Biol 23 (1996) 911-915
27. 18F]fluoroestradiol-3,17beta-disulphamate. Appl Radiat Isot 55 (2001) 631-639
28. 18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol 26 (1999) 905-913
29. Mankoff D.A., Tewson T.J., and Eary J.F. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluoroestradiol (FES). Nucl Med Biol 24 (1997) 341-348
30. 18F]fluoro)-17 beta-estradiol in DMBA-induced mammary tumors. Int J Rad Appl Instrum 14 (1987) 15-25
31. 18F]fluoro-17 beta-estradiol: A ligand for the in vivo assessment of estrogen receptor binding parameters. J Cereb Blood Flow Metab 15 (1995) 301-311
32. Moresco R.M., Scheithauer B.W., Lucignani G., et al. Oestrogen receptors in meningiomas: A correlative PET and immunohistochemical study. Nucl Med Commun 18 (1997) 606-615
33. 18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 42 (2001) 679-684
34. Dehdashti F., Flanagan F.L., Mortimer J.E., et al. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 26 (1999) 51-56
35. Dehdashti F., Mortimer J.E., Siegel B.A., et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36 (1995) 1766-1774
36. Linden H.M., Stekhova S.A., Link J.M., et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24 (2006) 2793-2799
37. Mintun M.A., Welch M.J., Siegel B.A., et al. Breast cancer: PET imaging of estrogen receptors. Radiology 169 (1988) 45-48
38. Mankoff D.A., Peterson L.M., Petra P.H., et al. Factors affecting the level and heterogeneity of uptake [F-18] fluroestardiol [FES] in patients with estrogen receptor positive breast cancer. J Nucl Med 43 (2002) 286-287
39. 18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 32 (1991) 1526-1531
40. 18F]fluoro-17beta-estradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 2 (1996) 933-939
41. Mortimer J.E., Dehdashti F., Siegel B.A., et al. Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19 (2001) 2797-2803
42. Linden H.M., Stekhova S., Link J.M., et al. Understanding resistance to hormonal therapy in estrogen avid breast cancer. ASCO Proc 24 suppl (2006) 566
43. Tsuchida T., Okazawa H., Mori T., et al. In vivo imaging of estrogen receptor concentration in the endometrium and myometrium using FES PET-influence of menstrual cycle and endogenous estrogen level. Nucl Med Biol 34 (2007) 205-210
44. 18F 17beta-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer. Gynecol Oncol 104 (2007) 764-766
45. Furukawa T., Lohith T.G., Takamatsu S., et al. Potential of the FES-hERL PET reporter gene system-basic evaluation for gene therapy monitoring. Nucl Med Biol 33 (2006) 145-151
46. Takamatsu S., Furukawa T., Mori T., et al. Noninvasive imaging of transplanted living functional cells transfected with a reporter estrogen receptor gene. Nucl Med Biol 32 (2005) 821-829